Small molecule compounds for treating lung epithelial and vascular endothelial cell injury
Summary
USPTO granted patent US12594282B2 to Guangzhou Cellprotek Pharmaceutical Co., Ltd. on April 7, 2026. The patent covers the use of 5α-androst-3β,5,6β-triol and analogues for treating pulmonary diseases mediated by lung epithelial cell injury and/or vascular endothelial cell injury. The compounds inhibit PFKFB3 expression and reduce vascular endothelial and alveolar epithelial cell injury.
What changed
USPTO granted patent US12594282B2 to Guangzhou Cellprotek Pharmaceutical Co., Ltd. covering the therapeutic use of 5α-androst-3β,5,6β-triol and its analogues for treating pulmonary diseases involving lung epithelial and vascular endothelial cell injury. The 11 granted claims describe methods of inhibiting PFKFB3 expression, reducing lactate accumulation, and treating conditions like alveolar damage and septum thickening.
For pharmaceutical manufacturers and biotech companies developing lung injury treatments, this patent establishes IP protection that may restrict the use of similar steroid-based compounds for pulmonary indications. Competitors will need to consider potential licensing arrangements or design-around strategies when developing related therapeutic candidates.
What to do next
- Monitor for potential licensing opportunities
- Review patent claims for freedom-to-operate analysis
- Track for any patent challenges or reexaminations
Archived snapshot
Apr 7, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Use of small molecule compounds in the treatment of diseases mediated by lung epithelial cell injury and/or vascular endothelial cell injury
Grant US12594282B2 Kind: B2 Apr 07, 2026
Assignee
Guangzhou Cellprotek Pharmaceutical Co., Ltd.
Inventors
Bingzheng Lu, Yupin Chen, Yana Wang, Jiayu Huang, Chunhui Huang, Jiesi Chen
Abstract
Disclosed is use of 5α-androst-3β,5,6β-triol or an analogue, a deuterated compound or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a pulmonary disease in a patient. These compounds can significantly inhibit the up-regulation of PFKFB3 expression, significantly inhibit the accumulation of lactate, significantly reduce vascular endothelial cell injury, significantly reduce alveolar epithelial cell injury, significantly inhibit alveolar septum thickening, significantly reduce alveolar damage, and thus can be used to treat diseases mediated by lung epithelial cell injury and/or vascular endothelial cell injury, such as in the lung.
CPC Classifications
A61P 11/00 A61K 31/56
Filing Date
2021-02-26
Application No.
17802870
Claims
11
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.